Apologies -- the two vaccines the WHO planned for Africa as I stated in perhaps another earlier post are Jynneos and the unlicensed Japanese vaccine, LC16m8. Which is described here:
While Jynneos is licensed in the US, the NIH is conducting a Phase 1 trial (safety only) on it now, and it is being used in the US under the PREP Act/CICP which is intended for unlicensed products or those used for an off label indication.
My point being is that the public knows very little about Jynneos despite its "license" and it does not have a license in Africa, which is why the WHO plans to prequalify it.
There is no bullshit here--you simply failed to read the earlier information as it became available.
Finally, while ACAM may be licened, the CDC admits it causes myocarditis in 5.7 people per thousand, which makes it unusable without a liability shield.
However the Jynneos?MVA etc vaccine also causes myocarditis at a rate undisclosed and that may be why NIH took it upon itself to do another Phase 1 study.
Jynneos was used (mostly off-label) n 2022-23 as a 1/5 dose, intradermal vaccine in about a million doses under CICP (liability waived) and we still don't know what those side effects were. But a 2% rate of serious adverse events and cardiac events in earlier trials ought to have everyone refuse it.
In my video I did mention you specifically named the vaccines in your follow-up article. I also let folks know your work on the Plandemic Treaty is the best out there just like your work on the AmeriThrax case was back in the day. Please keep it up, Dr. Nass.
Apologies -- the two vaccines the WHO planned for Africa as I stated in perhaps another earlier post are Jynneos and the unlicensed Japanese vaccine, LC16m8. Which is described here:
https://merylnass.substack.com/p/the-japanese-monkeypox-vaccine
While Jynneos is licensed in the US, the NIH is conducting a Phase 1 trial (safety only) on it now, and it is being used in the US under the PREP Act/CICP which is intended for unlicensed products or those used for an off label indication.
My point being is that the public knows very little about Jynneos despite its "license" and it does not have a license in Africa, which is why the WHO plans to prequalify it.
There is no bullshit here--you simply failed to read the earlier information as it became available.
Today, this is what the WHO says about vaccines for moneypox:
"At present, WHO recommends use of MVA-BN or LC16 vaccines, or the ACAM2000 vaccine when the others are not available."
https://www.who.int/news-room/questions-and-answers/item/monkeypox/
Finally, while ACAM may be licened, the CDC admits it causes myocarditis in 5.7 people per thousand, which makes it unusable without a liability shield.
However the Jynneos?MVA etc vaccine also causes myocarditis at a rate undisclosed and that may be why NIH took it upon itself to do another Phase 1 study.
Jynneos was used (mostly off-label) n 2022-23 as a 1/5 dose, intradermal vaccine in about a million doses under CICP (liability waived) and we still don't know what those side effects were. But a 2% rate of serious adverse events and cardiac events in earlier trials ought to have everyone refuse it.
Thanks for pointing out what I need to make clearer.
In my video I did mention you specifically named the vaccines in your follow-up article. I also let folks know your work on the Plandemic Treaty is the best out there just like your work on the AmeriThrax case was back in the day. Please keep it up, Dr. Nass.